The San Diego-based pharmaceutical company Prometheus Laboratories has launched PROMETHEUS Anser VDZ, a monitoring test for inflammatory bowel disease patients using vedolizumab.
Here's what you need to know:
1. The PROMETHEUS Anser test portfolio measures drug concentrations of various IBD treatments and antidrug antibody levels, to help physicians make individualized treatment decisions.
2. The company's portfolio already includes monitoring tests for anti-TNF agents, including infliximab, infliximab biosimilars and adalimumab.
3. With PROMETHEUS Anser VDZ, the company can now monitor patients being treated with vedolizumab, an IBD treatment commercialized by Takeda Pharmaceutical under the brand name Entyvio.